Filing Details

Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001193125-22-218472)

NAMES OF REPORTING PERSONS

ATHYRIUM OPPORTUNITIES IV ACQUISITION 2 LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐ (b) ☐

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

STATE OF DELAWARE, UNITED STATES OF AMERICA

Accession Number:: 0001193125-22-218472
Form Type:: 13G Filing
Publication Date:: 2022-08-10 20:00:00

Filed By:: Athyrium Opportunities Iv Acquisition 2 Lp
Company:: Rvl Pharmaceuticals Plc
Filing Date:: 2022-08-11
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
ATHYRIUM OPPORTUNITIES IV ACQUISITION	8,148,832	8,148,832	8,148,832	8.23%
ATHYRIUM OPPORTUNITIES ASSOCIATES IV	8,148,832	8,148,832	8,148,832	8.23%
ATHYRIUM OPPORTUNITIES ASSOCIATES IV GP	8,148,832	8,148,832	8,148,832	8.23%
ATHYRIUM OPPORTUNITIES IV CO-INVEST	6,451,612	6,451,612	6,451,612	6.52%
ATHYRIUM OPPORTUNITIES ASSOCIATES IV CO-INVEST	6,451,612	6,451,612	6,451,612	6.52%
ATHYRIUM FUNDS GP HOLDINGS	14,600,444	14,600,444	14,600,444	14.75%
Jeffrey A. Ferrell	14,600,444	14,600,444	14,600,444	14.75%

Filing

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED

PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO § 240.13d-2

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

RVL Pharmaceuticals plc

(Name of Issuer)

Ordinary Shares, nominal value $0.01 per share

(Title of Class of Securities)

G6S41R101

(CUSIP Number)

August 8, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐

Rule 13d-1(b)

☒

Rule 13d-1(c)

☐

Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP NO. G6S41R101		13G		Page 2 of 13 Pages


CUSIP NO. G6S41R101		13G		Page 3 of 13 Pages


CUSIP NO. G6S41R101		13G		Page 4 of 13 Pages


CUSIP NO. G6S41R101		13G		Page 5 of 13 Pages


CUSIP NO. G6S41R101		13G		Page 6 of 13 Pages


CUSIP NO. G6S41R101		13G		Page 7 of 13 Pages


CUSIP NO. G6S41R101		13G		Page 8 of 13 Pages


CUSIP NO. G6S41R101		13G		Page 9 of 13 Pages

Item 1(a).

Name of Issuer:

RVL Pharmaceuticals plc (the Issuer)

Item 1(b).

Address of Issuers Principal Executive Offices:

400 Crossing Boulevard

Bridgewater, New Jersey 08807

Item 2(a).

Name of Person Filing:

This statement (this Statement) is filed by the following persons (the Reporting Persons):

Athyrium Opportunities IV Acquisition 2 LP (Acquisition Fund)

Athyrium Opportunities Associates IV LP (Associates IV LP)

Athyrium Opportunities Associates IV GP LLC (Associates IV GP)

Athyrium Opportunities IV Co-Invest 2 LP (Co-Invest 2 LP)

Athyrium Opportunities Associates IV Co-Invest LLC (Co-Invest LLC)

Athyrium Funds GP Holdings LLC (Funds GP Holdings)

Jeffrey A. Ferrell (Mr. Ferrell)

The Reporting Persons beneficial ownership of the Issuers Ordinary Shares reported herein consist of ordinary shares, nominal value $0.01 per share, held directly by Acquisition Fund and Co-Invest 2 LP.

Pursuant to Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, which agreement is set forth on the signature page to this Statement.

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The principal business office address for each of the Reporting Persons is:

c/o Athyrium Capital Management, LP

505 Fifth Avenue, Floor 18

New York, New York 10017

Item 2(c).

Citizenship:

Acquisition Fund, Co-Invest 2 LP and Associates IV LP are Delaware limited partnerships.

Associates IV GP, Co-Invest LLC and Funds GP Holdings are Delaware limited liability companies.

Mr. Ferrell is a United States citizen.

Item 2(d).

Title of Class of Securities:

Ordinary Shares, nominal value $0.01 per share, of the Issuer (the Ordinary Shares)

Item 2(e).

CUSIP Number:

G6S41R101


CUSIP NO. G6S41R101		13G		Page 10 of 13 Pages

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable. Filed pursuant to Rule 13d-1(c).

Item 4.

Ownership.

(a)

Amount beneficially owned:

The Reporting Persons beneficially own in the aggregate 14,600,444 Ordinary Shares. In addition, certain of the Reporting Persons beneficially own warrants (the Warrants) to purchase 2,000,000 Ordinary Shares. However, because the terms of the Warrants limit the exercise of the Warrants while the Reporting Persons beneficial ownership of the Issuers Ordinary Shares exceeds 9.9% of the outstanding Ordinary Shares, the Warrants held by the Reporting Persons do not represent a right to receive Ordinary Shares within 60 days of the date of this Statement and therefore none of the shares issuable upon exercise of the Warrants are included herein.

(b)

Percent of class:

See the responses to Item 11 on the attached cover pages.

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote:

See the responses to Item 5 on the attached cover pages.

(ii)

Shared power to vote or to direct the vote:

See the responses to Item 6 on the attached cover pages.

(iii)

Sole power to dispose or to direct the disposition of:

See the responses to Item 7 on the attached cover pages.

(iv)

Shared power to dispose or to direct the disposition of:

See the responses to Item 8 on the attached cover pages.

The filing of this Statement shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.


CUSIP NO. G6S41R101		13G		Page 11 of 13 Pages

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


CUSIP NO. G6S41R101		13G		Page 12 of 13 Pages

SIGNATURES

After reasonable inquiry and to the best of each of the undersigneds knowledge and belief, each of the undersigned certifies that the information set forth in this Statement is true, complete and correct.

In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Statement on Schedule 13G with respect to the Ordinary Shares of the Issuer.

Dated: August 11, 2022


ATHYRIUM OPPORTUNITIES IV ACQUISITION 2 LP

By:	ATHYRIUM OPPORTUNITIES ASSOCIATES IV LP, its General Partner

	By:	ATHYRIUM OPPORTUNITIES ASSOCIATES IV GP LLC, its General Partner

	By:	/s/ Andrew Hyman
	Name:	Andrew Hyman
	Title:	Senior Vice President, Secretary


ATHYRIUM OPPORTUNITIES ASSOCIATES IV LP

By:		ATHYRIUM OPPORTUNITIES ASSOCIATES IV GP LLC, its General Partner

By:		/s/ Andrew Hyman
Name:		Andrew Hyman
Title:		Senior Vice President, Secretary

ATHYRIUM OPPORTUNITIES ASSOCIATES IV GP LLC

By:		/s/ Andrew Hyman
Name:		Andrew Hyman
Title:		Senior Vice President, Secretary


CUSIP NO. G6S41R101		13G		Page 13 of 13 Pages


ATHYRIUM OPPORTUNITIES IV CO-INVEST 2 LP

By: ATHYRIUM OPPORTUNITIES ASSOCIATES IV CO-INVEST LLC, its General Partner

By:		/s/ Andrew Hyman
Name:		Andrew Hyman
Title:		Senior Vice President, Secretary

ATHYRIUM OPPORTUNITIES ASSOCIATES IV CO-INVEST LLC

By:		/s/ Andrew Hyman
Name:		Andrew Hyman
Title:		Senior Vice President, Secretary

ATHYRIUM FUNDS GP HOLDINGS LLC

By:		/s/ Jeffrey A. Ferrell
Name:		Jeffrey A. Ferrell
Title:		Managing Member

/s/ Jeffrey A. Ferrell

JEFFREY A. FERRELL